An interventional study of Tamoxifen in Breast Cancer, sponsored by Nalagenetics Pte Ltd. Status unknown at 1 site in Indonesia. Open to female participants. Per ClinicalTrials.gov, last updated 2022-08-19.
Sponsored by Nalagenetics Pte Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 133 studies testing tamoxifen in Breast Neoplasms — 16 open to participants now, 30 under way, 9 of them phase 3. Tamoxifen · Breast Neoplasms.
Among the 133 studies testing tamoxifen in Breast Neoplasms, this one is the 65th largest by enrollment of the 126 interventional ones that give a count, is one of 5 that started in 2021, is one of 9 with no phase, and was the 120th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →16 of the 133 studies testing tamoxifen in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Fujian Cancer Hospital · Sites in China
Ages 18+ · Women only
Andrea DeCensi · Sites in Italy
Women only
National Cancer Institute (NCI) · Sites in United States
Ages 45–74 · Women only · Healthy volunteers
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
By country, each count listing its studies:
Tamoxifen: first FDA approval 1977 (NOLVADEX). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
133 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 57 · Phase 3 58 · Phase 4 4
First in 1987; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 169 across the 126 interventional studies. Of the 80 that completed or were terminated, 33 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 133 have an industry lead sponsor. The 10 most frequent:
Nalagenetics Pte Ltd is the lead sponsor of 5 studies on the registry; none are open to participants now.
Nalagenetics Pte Ltd has 4 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies testing tamoxifen in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05780567Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | 2026-12 |
| NCT04174352University of Wisconsin, MadisonFES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer | 2026-12 |
| NCT06195306National Cancer Institute (NCI)Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction | 2027-01-01 |
| NCT02476786Washington University School of MedicineEndocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | 2027-01-31 |
| NCT06364267Andrea DeCensiLow Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer. | 2027-01-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 133 studies testing tamoxifen in Breast Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The utilization of tamoxifen is considerably high in Indonesia, with about 170,000 tamoxifen prescriptions filed in 2015. It is metabolized by the enzyme CYP2D6, resulting in its active metabolite, endoxifen, which has been proven to be effective in the prevention and treatment of breast cancer.
Studies showed the CYP2D6 gene has more than 100 variants; some of which are linked with reduced drug activity, while others do not have any pathological implications. The metabolizer profile of these variants is generally grouped into Ultra-rapid, Normal, Intermediate, and Poor Metabolizers (UM, NM, IM, and PM, respectively). In our previous study (NCT04312347), the investigators recruited 150 breast cancer patients who were taking adjusted dose of tamoxifen daily based on their CYP2D6 phenotype. Although the investigators have measured the endoxifen level of the patients with adjusted treatment, the clinical outcomes of the study are not yet conclusive.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Following the CPIC guidelines, those identified as Poor Metabolizers (PMs) and Intermediate Metabolizers (IMs) from our previous study are recommended to adjust their tamoxifen dosage to 40 mg per day.
Drug: Tamoxifen
Those identified as Normal Metabolizers (NMs) from our previous study remain on tamoxifen 20 mg per day.
Suggesting an increase in the dose of tamoxifen to those who have suboptimum level of endoxifen due to their genetic variations
Overall Survival rate
The percentage of study participants who are still alive by the end of this study after being diagnosed with breast cancer
Time frame: 3 year
Progression Survival rate
The percentage of study participants who live with the disease but the disease does not get worse by the end of this study
Time frame: 3 year
Long-term side effects of tamoxifen
Long-term side effects of tamoxifen, including heartburn, thromboembolic event, endometrial hyperplasia and uterine cancer, will also be monitored and documented using the Adverse Drug Reaction (ADR) reporting form provided by the Indonesian National Agency of Drug and Food Control.
Time frame: 3 year
Plan to share: No
Started Jan 2021 (actual). Primary completion is estimated for Apr 2024, 39 months after the start.
Of 110 industry-sponsored interventional studies with no phase under Breast Neoplasms, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 59. This study's planned 39 months is above that.
Counting every sponsor, half of 2,774 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tamoxifen
Nalagenetics Pte Ltd